Immunotherapy has changed the treatment landscape for cancer over the past decade.
Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4 …

Immune checkpoint inhibitor (ICI) therapy has revolutionized the field of oncology over the
past decade, leading to durable remissions in some patients but also producing a wide …

Immunotherapy with immune checkpoint inhibitors (ICIs) nowadays has indications for
several solid tumors. The current targets for ICIs are CTLA-4, PD-1, and PD-L1 receptors …

Abstract Purpose of Review Immune checkpoint inhibitor (ICI) therapy revolutionized the
treatment of multiple solid and hematologic malignancies. Yet, with it came profound …

PD-1 inhibitors, as one of commonly used immune checkpoint inhibitors, enable T-cell
activation and prevent immune escape by blocking the PD-1/PD-L1 signaling pathway. They …

Introduction: Immune checkpoint inhibitors (ICI) are used to treat various malignancies. They
block the inhibitory signals of tumor cells and enhance the inflammatory cascade, which …

Immune checkpoint inhibitors are increasingly used as adjuvant therapy in oncology;
however, they have short and long-term side effects. A major one is the surge in …

Introduction Dermatitis herpetiformis (DH) is a rare autoimmune, polymorphous blistering
disorder, characterized by severe itch or burning sensation, which represents the cutaneous …

Immune checkpoint inhibitors (ICIs) have become the most frequently utilized
immunotherapy in solid tumors. Following their success in treating melanoma and lung …

The review of publications on the safety profiles of three different immunosuppressants and
immunomodulators (Alemtuzumab (ALZ), ipilimumab and nivolumab) published between …